Posted by Michael Wonder on 16 Nov 2021
PHARMAC widens access to adalimumab through transition to biosimilar
17 November 2021 - Pharmac’s chief medical officer Dr David Hughes has today announced the decision to fund a biosimilar adalimumab (Amgevita), improving access to adalimumab for more than 700 New Zealanders.
Amgevita will be available from 1 March 2022.
